{
  "kind": "treatment",
  "slug": "perampanel-fycompa",
  "type": "medication",
  "name": "Perampanel (Fycompa)",
  "summary": "Perampanel is an oral antiepileptic medication used to treat partial-onset seizures and primary generalized tonic-clonic seizures.",
  "description": "Perampanel, marketed under the brand name Fycompa, is a selective, noncompetitive antagonist of the AMPA receptor, a subtype of the glutamate receptor in the central nervous system. By inhibiting excitatory neurotransmission mediated by AMPA receptors, perampanel reduces neuronal hyperexcitability associated with seizures. It is indicated for the treatment of partial-onset seizures with or without secondary generalization in patients aged 4 years and older, and for primary generalized tonic-clonic seizures in patients aged 12 years and older.",
  "category": "medications/antiepileptics",
  "tags": [
    "antiepileptic",
    "anticonvulsant",
    "seizure control",
    "AMPA receptor antagonist"
  ],
  "metadata": {
    "drug_classes": [
      "Antiepileptic"
    ],
    "therapeutic_categories": [
      "Neurology"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription only",
    "controlled_substance": true,
    "controlled_schedule_us": "Schedule III",
    "generic_available": false,
    "brand_names": [
      "Fycompa"
    ],
    "age_groups": [
      "Pediatric",
      "Adult"
    ],
    "treatment_duration": [
      "Chronic use"
    ],
    "specialty_areas": [
      "Neurology",
      "Epileptology"
    ],
    "fda_approval_year": 2012
  },
  "clinical_metadata": {
    "primary_indications": [
      "Seizures"
    ],
    "off_label_uses": [
      "Seizures in Lennox-Gastaut syndrome (investigational)"
    ],
    "contraindications": [
      "Known hypersensitivity to perampanel or any component of the formulation",
      "History of serious psychiatric or behavioral reactions related to perampanel"
    ],
    "monitoring_required": [
      "Seizure frequency and severity",
      "Mood and behavior changes",
      "Signs of aggression or hostility",
      "Suicidal ideation"
    ],
    "efficacy_rating": {
      "Partial-onset seizures": 5,
      "Primary generalized tonic-clonic seizures": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "perampanel",
      "Fycompa",
      "AMPA receptor antagonist",
      "antiepileptic drug"
    ],
    "synonyms": [
      "Fycompa"
    ],
    "common_misspellings": [
      "perampanil",
      "perampenal"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Treatment of partial-onset seizures with or without secondary generalization in patients 4 years and older",
        "Treatment of primary generalized tonic-clonic seizures in patients 12 years and older"
      ]
    },
    {
      "type": "mechanism",
      "text": "Perampanel is a selective, noncompetitive antagonist of the AMPA receptor, a subtype of ionotropic glutamate receptor, which inhibits excitatory neurotransmission and reduces neuronal hyperexcitability."
    },
    {
      "type": "dosing",
      "adult": {
        "Partial-Onset Seizures": "Initial: 2 mg orally once daily at bedtime; increase by 2 mg/day at weekly intervals up to a maximum of 12 mg/day based on response and tolerability.",
        "Primary Generalized Tonic-Clonic Seizures": "Initial: 2 mg orally once daily at bedtime; increase by 2 mg/day at weekly intervals to a maximum of 8â€“12 mg/day."
      },
      "pediatric": "Similar dosing schedule for patients aged 4 years and older, adjusted for tolerability.",
      "renal_hepatic_impairment": "Moderate or severe hepatic impairment: maximum dose 6 mg/day; not recommended in severe renal impairment or hemodialysis."
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg",
        "Oral suspension: 0.5 mg/mL"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Therapeutic effects may be observed within the first few weeks of treatment as dosing is titrated to the effective range."
    },
    {
      "type": "adverse_effects",
      "common": [
        "dizziness",
        "somnolence",
        "fatigue",
        "headache",
        "irritability",
        "weight gain"
      ],
      "less_common": [
        "ataxia",
        "blurred vision",
        "nausea"
      ],
      "serious": [
        "serious psychiatric and behavioral reactions",
        "suicidal ideation",
        "falls",
        "homicidal ideation (rare)"
      ]
    },
    {
      "type": "warnings",
      "black_box": "May cause serious psychiatric and behavioral reactions, including aggression, hostility, irritability, anger, and homicidal ideation.",
      "other": [
        "Use caution in patients with a history of psychiatric disorders",
        "Gradual dose titration recommended to minimize adverse effects",
        "Monitor closely during initial titration and dosage increases"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin)",
          "risk": "Reduced perampanel plasma levels",
          "action": "May require higher dose"
        },
        {
          "with": "CNS depressants",
          "risk": "Additive sedation",
          "action": "Monitor and adjust dose as needed"
        },
        {
          "with": "Alcohol",
          "risk": "Enhanced CNS effects including dizziness and sedation",
          "action": "Avoid concurrent use"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Seizure frequency",
        "Mood and behavior changes",
        "Weight changes",
        "Signs of suicidal ideation"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "No adequate data; use only if potential benefits justify potential risks.",
      "lactation": "Unknown if excreted in breast milk; caution advised.",
      "pediatrics": "Approved for use in children 4 years and older for partial-onset seizures."
    },
    {
      "type": "tapering",
      "text": "Gradual dose reduction recommended to minimize the risk of increased seizure frequency."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Has a long half-life (~105 hours), allowing once-daily dosing",
        "Schedule III controlled substance in the US due to potential for abuse",
        "Behavioral monitoring is essential during treatment"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Fycompa Prescribing Information",
          "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202834s017lbl.pdf"
        },
        {
          "label": "Drugs.com - Perampanel",
          "url": "https://www.drugs.com/fycompa.html"
        }
      ]
    }
  ],
  "seo": {
    "title": "Perampanel (Fycompa) - Uses, Dosing, Side Effects, Warnings",
    "description": "Perampanel (Fycompa) is an AMPA receptor antagonist used to treat partial-onset and primary generalized tonic-clonic seizures. Learn dosing, side effects, and warnings."
  }
}
